Mammography trends show improved cancer detection, more biopsies


Credit: Radiological Society of North America

OAK BROOK, Ill. – The shift from film to digital technology appears to have improved cancer detection rates for diagnostic mammography, but also has increased the abnormal interpretation rate, which may lead to more women undergoing biopsies for benign conditions, according to a new study that appears online in the journal Radiology.

The major new study comes from the National Cancer Institute-funded Breast Cancer Surveillance Consortium (BCSC), a large, diverse set of breast imaging facilities that provides data linked to state cancer registries to help evaluate breast cancer screening and diagnosis in the United States.

In 2005, the consortium released a study on the performance of diagnostic mammography in the U.S. Diagnostic mammography is used for women presenting with clinical signs and symptoms, a recent abnormal screening mammogram, or who are undergoing short-interval follow-up for a finding previously assessed as probably benign. At the time of the previous BCSC report, film mammography was the standard. With digital technology replacing film, the researchers decided it was time to revisit the old benchmarks, according to study lead author Brian L. Sprague, Ph.D., from the University of Vermont Cancer Center in Burlington, Vt. The university leads one of several active registries in the BCSC.

"Our goals in this study were to produce benchmarks that individual radiologists and breast imaging facilities can use to compare with their own practices and to convey trends in how the metrics have changed over the past 10 to 15 years," Dr. Sprague said.

This study included data from six BCSC registries comprising 418 radiologists and 92 radiology facilities. Mammography indication and assessments were collected on women undergoing diagnostic digital mammography and linked with cancer diagnoses from state cancer registries. The database included 401,548 examinations conducted from 2007 to 2013 on 265,360 women.

Comparison with the results from the earlier BCSC benchmarks publication revealed that the cancer detection rate rose from 25.3 per 1,000 in 2005 to 34.7 per 1,000 in the new study. The change likely reflects improvements in mammography imaging technology, which permit the visualization of smaller lesions and greater detection of calcifications that result in increased cancer detection, the researchers said.

Alongside improved cancer detection, some less desirable trends emerged. The abnormal interpretation rate, or the rate at which women are called back for biopsy, rose from 8.0 percent in 2005 to 12.6 percent in the new study.

"While the improvements in cancer detection rates are encouraging, the increased abnormal interpretation rate is somewhat troubling in that we're trying to keep this rate down," Dr. Sprague said.

An increase in mammographic cancer detection does not necessarily have to come with a substantial rise in the abnormal interpretation rate, Dr. Sprague noted. For instance, Europe has been able to achieve cancer detection rates similar to U.S. rates with much lower abnormal interpretation rates. Increased utilization of double reading in Europe, where at least two radiologists interpret the same exam, may be a factor. In addition, variables like fear of litigation can affect abnormal interpretation rates, Dr. Sprague said.

Another concerning trend was the drop in positive predictive value (PPV), or the probability that patients with a positive diagnostic mammogram truly have a malignancy. PPV for a biopsy recommended (PPV2) fell from 31.5 percent in 2005 to 27.5 percent in the new study. The lower PPV2 results from the abnormal interpretation rate increasing much more than the cancer detection rate, the researchers said, suggesting that improvements in imaging may do more to permit the visualization of additional findings than helping in discriminating benign from malignant findings.

"The results of the study highlight specific areas where quality improvement initiatives should focus," Dr. Sprague said. "Overall, there is a lot of good performance out there, but there are definitely areas for improvement in positive predictive value and abnormal interpretation rate."


"National Performance Benchmarks for Modern Diagnostic Digital Mammography: Update from the Breast Cancer Surveillance Consortium." Collaborating with Dr. Sprague were Robert F. Arao, M.P.H., Diana L. Miglioretti, Ph.D., Louise M. Henderson, Ph.D., Diana S. M. Buist, Ph.D., M.P.H., Tracy Onega, Ph.D., Garth H. Rauscher, Ph.D., M.P.H., Janie M. Lee, M.D., M.S., Anna N. A. Tosteson, Sc.D., Karla Kerlikowske, M.D., M.S., and Constance D. Lehman, M.D., Ph.D., for the Breast Cancer Surveillance Consortium.

Radiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc.

RSNA is an association of 54,000 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Ill. (

For patient-friendly information on breast screening, visit

Media Contact

Linda Brooks
[email protected]

1 Comment
  1. Niyos Eileen says

    What the public must know is what is NOT mentioned here…

    The biggest issue is that it’s not just “the increased abnormal interpretation rate” with digital mammography that a huge issue but that early, or earlier, detection does not mean that there is less breast cancer mortality, or serious harm. On the contrary, opposing the official narrative (which is based on medical business-fabricated pro-mammogram “scientific” data), there is marginal, if any, reliable evidence that mammography, whether conventional or digital (3D), reduces mortality from breast cancer in a significant way in any age bracket but a lot of solid evidence shows the procedure does provide more serious harm than serious benefit (read the books: ‘Mammography Screening: Truth, Lies and Controversy’ by Peter Gotzsche and ‘The Mammogram Myth’ by Rolf Hefti).

    IF…….. women (and men) at large were to examine the mammogram data above and beyond the information of the mammogram business cartel (eg American Cancer Society, National Cancer Institute, Komen), they’d also find that it is almost exclusively the big profiteers of the test, ie. the “experts,” (eg radiologists, oncologists, medical trade associations, breast cancer “charities,”, breast screening equipment manufacturers, etc) who promote the mass use of the test and that most pro-mammogram “research” is conducted by people with massive vested interests tied to the mammogram industry.

    Most women are fooled by the misleading medical mantra that early detection by mammography saves lives simply because the public has been fed (“educated” or rather brainwashed) with a very one-sided biased pro-mammogram set of information circulated by the big business of mainstream medicine.

    Because of this one-sided promotion and marketing of the test by the medical business, women have been obstructed from making an “informed choice” about its benefits and risks which have been inaccurately depicted by the medical industry, favoring their business interests.

    Operating and reasoning based on this false body of information is the reason why very few women understand, for example, that a lot of breast cancer survivors are victims of harm instead of receivers of benefit. Therefore, almost all breast cancer “survivors” blindly repeat the official profitable medical propaganda.

Leave A Reply

Your email address will not be published.